BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025

Core Insights - BridgeBio Pharma, Inc. is a biopharmaceutical company focused on genetic diseases, participating in the Bank of America Merrill Lynch Global Healthcare Conference 2025 [1][3] - The company aims to discover, create, test, and deliver transformative medicines for patients with genetic diseases, with a pipeline that includes early science to advanced clinical trials [3] Company Overview - Founded in 2015, BridgeBio is committed to applying advances in genetic medicine to expedite patient care [3] - The company has a team of experienced professionals in drug discovery and development [3] Event Participation - Management will engage in a fireside chat at the conference on May 14, 2025, at 2:20 pm PT [1] - A live webcast of the presentation will be available on the company's website, with a replay accessible for 30 days post-event [2]